141 related articles for article (PubMed ID: 29967289)
1. Identifying a missing lineage driver in a subset of lung neuroendocrine tumors.
Pozo K; Minna JD; Johnson JE
Genes Dev; 2018 Jul; 32(13-14):865-867. PubMed ID: 29967289
[TBL] [Abstract][Full Text] [Related]
2. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer.
Huang YH; Klingbeil O; He XY; Wu XS; Arun G; Lu B; Somerville TDD; Milazzo JP; Wilkinson JE; Demerdash OE; Spector DL; Egeblad M; Shi J; Vakoc CR
Genes Dev; 2018 Jul; 32(13-14):915-928. PubMed ID: 29945888
[TBL] [Abstract][Full Text] [Related]
3. POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC.
Baine MK; Febres-Aldana CA; Chang JC; Jungbluth AA; Sethi S; Antonescu CR; Travis WD; Hsieh MS; Roh MS; Homer RJ; Ladanyi M; Egger JV; Lai WV; Rudin CM; Rekhtman N
J Thorac Oncol; 2022 Sep; 17(9):1109-1121. PubMed ID: 35760287
[TBL] [Abstract][Full Text] [Related]
4. POU2F3: A Sensitive and Specific Diagnostic Marker for Neuroendocrine-low/negative Small Cell Lung Cancer.
Wang Y; Jin Y; Shen X; Zheng Q; Xue Q; Chen L; Lin Y; Li Y
Am J Surg Pathol; 2023 Sep; 47(9):1059-1066. PubMed ID: 37357936
[TBL] [Abstract][Full Text] [Related]
5. Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma.
Koh J; Kim H; Moon KC; Lee C; Lee K; Ryu HS; Jung KC; Jeon YK
Am J Surg Pathol; 2023 Feb; 47(2):183-193. PubMed ID: 36253891
[TBL] [Abstract][Full Text] [Related]
6. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.
Baine MK; Hsieh MS; Lai WV; Egger JV; Jungbluth AA; Daneshbod Y; Beras A; Spencer R; Lopardo J; Bodd F; Montecalvo J; Sauter JL; Chang JC; Buonocore DJ; Travis WD; Sen T; Poirier JT; Rudin CM; Rekhtman N
J Thorac Oncol; 2020 Dec; 15(12):1823-1835. PubMed ID: 33011388
[TBL] [Abstract][Full Text] [Related]
7. Killing SCLC: insights into how to target a shapeshifting tumor.
Sutherland KD; Ireland AS; Oliver TG
Genes Dev; 2022 Mar; 36(5-6):241-258. PubMed ID: 35318269
[TBL] [Abstract][Full Text] [Related]
8. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.
Augustyn A; Borromeo M; Wang T; Fujimoto J; Shao C; Dospoy PD; Lee V; Tan C; Sullivan JP; Larsen JE; Girard L; Behrens C; Wistuba II; Xie Y; Cobb MH; Gazdar AF; Johnson JE; Minna JD
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14788-93. PubMed ID: 25267614
[TBL] [Abstract][Full Text] [Related]
9. POU2AF2/C11orf53 functions as a coactivator of POU2F3 by maintaining chromatin accessibility and enhancer activity.
Szczepanski AP; Tsuboyama N; Watanabe J; Hashizume R; Zhao Z; Wang L
Sci Adv; 2022 Oct; 8(40):eabq2403. PubMed ID: 36197978
[TBL] [Abstract][Full Text] [Related]
10. OCA-T1 and OCA-T2 are coactivators of POU2F3 in the tuft cell lineage.
Wu XS; He XY; Ipsaro JJ; Huang YH; Preall JB; Ng D; Shue YT; Sage J; Egeblad M; Joshua-Tor L; Vakoc CR
Nature; 2022 Jul; 607(7917):169-175. PubMed ID: 35576971
[TBL] [Abstract][Full Text] [Related]
11. Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity.
Udyavar AR; Wooten DJ; Hoeksema M; Bansal M; Califano A; Estrada L; Schnell S; Irish JM; Massion PP; Quaranta V
Cancer Res; 2017 Mar; 77(5):1063-1074. PubMed ID: 27932399
[TBL] [Abstract][Full Text] [Related]
12. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
[TBL] [Abstract][Full Text] [Related]
13. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.
Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H
Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040
[TBL] [Abstract][Full Text] [Related]
14. A Tuft Cell-Like Signature Is Highly Prevalent in Thymic Squamous Cell Carcinoma and Delineates New Molecular Subsets Among the Major Lung Cancer Histotypes.
Yamada Y; Simon-Keller K; Belharazem-Vitacolonnna D; Bohnenberger H; Kriegsmann M; Kriegsmann K; Hamilton G; Graeter T; Preissler G; Ott G; Roessner ED; Dahmen I; Thomas RK; Ströbel P; Marx A
J Thorac Oncol; 2021 Jun; 16(6):1003-1016. PubMed ID: 33609752
[TBL] [Abstract][Full Text] [Related]
15. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.
Ogino A; Choi J; Lin M; Wilkens MK; Calles A; Xu M; Adeni AE; Chambers ES; Capelletti M; Butaney M; Gray NS; Gokhale PC; Palakurthi S; Kirschmeier P; Oxnard GR; Sholl LM; Jänne PA
Mol Oncol; 2021 Jan; 15(1):27-42. PubMed ID: 32191822
[TBL] [Abstract][Full Text] [Related]
16. Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells.
Kudoh S; Tenjin Y; Kameyama H; Ichimura T; Yamada T; Matsuo A; Kudo N; Sato Y; Ito T
Histochem Cell Biol; 2020 Jun; 153(6):443-456. PubMed ID: 32170367
[TBL] [Abstract][Full Text] [Related]
17. SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures.
Tlemsani C; Pongor L; Elloumi F; Girard L; Huffman KE; Roper N; Varma S; Luna A; Rajapakse VN; Sebastian R; Kohn KW; Krushkal J; Aladjem MI; Teicher BA; Meltzer PS; Reinhold WC; Minna JD; Thomas A; Pommier Y
Cell Rep; 2020 Oct; 33(3):108296. PubMed ID: 33086069
[TBL] [Abstract][Full Text] [Related]
18. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.
Borromeo MD; Savage TK; Kollipara RK; He M; Augustyn A; Osborne JK; Girard L; Minna JD; Gazdar AF; Cobb MH; Johnson JE
Cell Rep; 2016 Aug; 16(5):1259-1272. PubMed ID: 27452466
[TBL] [Abstract][Full Text] [Related]
19. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.
Jahchan NS; Dudley JT; Mazur PK; Flores N; Yang D; Palmerton A; Zmoos AF; Vaka D; Tran KQ; Zhou M; Krasinska K; Riess JW; Neal JW; Khatri P; Park KS; Butte AJ; Sage J
Cancer Discov; 2013 Dec; 3(12):1364-77. PubMed ID: 24078773
[TBL] [Abstract][Full Text] [Related]
20.
Voigt E; Wallenburg M; Wollenzien H; Thompson E; Kumar K; Feiner J; McNally M; Friesen H; Mukherjee M; Afeworki Y; Kareta MS
Mol Cancer Res; 2021 Dec; 19(12):2015-2025. PubMed ID: 34593608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
